Estados financieros detallados de CRISPR Therapeutics AG (CRSP): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
CRISPR Therapeutics AG registró ingresos de $3.5M en el último ejercicio fiscal, con un CAGR de 5 años del 37.3%.
Márgenes de los últimos 12 meses: margen bruto -15.3%, margen operativo -39.7%, margen neto -33.7%.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | $5.2M | $41.0M | $3.1M | $289.6M | $719000 | $913.1M | $436000 | $370.0M | $35.0M | $3.5M |
| Coste de Ventas | $42.2M | $69.8M | $113.8M | $179.4M | $269.4M | $101.2M | $110.2M | $130.2M | $110.2M | $233.0M |
| Beneficio Bruto | -$37.1M | -$28.8M | -$110.6M | $110.2M | -$268.7M | $811.9M | -$109.8M | $239.8M | -$75.2M | -$229.4M |
| I+D | $42.2M | $69.8M | $113.8M | $179.4M | $221.4M | $340.6M | $461.6M | $387.3M | $320.7M | $265.3M |
| Generales y Administrativos | $31.1M | $35.8M | $48.3M | $63.5M | $85.7M | $99.7M | $102.5M | $76.2M | $73.0M | $73.5M |
| Gastos Operativos | $73.3M | $105.6M | $162.1M | $63.5M | $85.7M | $438.4M | $563.3M | $462.3M | $391.3M | $338.9M |
| Beneficio Operativo | -$68.1M | -$64.6M | -$158.9M | $46.7M | -$354.4M | $373.5M | -$673.2M | -$222.5M | -$466.6M | -$568.3M |
| EBITDA | -$13.7M | -$61.6M | -$155.4M | $51.5M | -$345.3M | $397.5M | -$626.3M | -$130.9M | -$343.4M | -$558.5M |
| Gastos por Intereses | $8.1M | 0 | 0 | | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$22.7M | -$66.6M | -$164.4M | $67.3M | -$348.1M | $379.5M | -$650.5M | -$150.7M | -$362.7M | -$578.0M |
| Impuestos | $484000 | $1.7M | $553000 | $448000 | $809000 | $1.9M | -$325000 | $2.9M | $3.6M | $3.6M |
| Beneficio Neto | -$23.2M | -$68.4M | -$165.0M | $66.9M | -$348.9M | $377.7M | -$650.2M | -$153.6M | -$366.3M | -$581.6M |
| BPA | $-1.89 | $-1.71 | $-3.44 | $1.23 | $-5.29 | $4.97 | $-8.36 | $-1.94 | $-4.34 | $-6.47 |
| BPA Diluido | $-1.89 | $-1.71 | $-3.44 | $1.17 | $-5.29 | $4.70 | $-8.36 | $-1.94 | $-4.34 | $-6.47 |
| Acciones en Circulación (Diluidas) | $12.3M | $40.1M | $48.0M | $56.9M | $65.9M | $80.4M | $77.7M | $79.2M | $84.4M | $89.9M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | $889000 | $864000 | $1.5M | $10.2M |
| Beneficio Bruto | -$63.8M | -$58.5M | -$48.8M | -$34.4M |
| Beneficio Operativo | -$132.1M | -$154.8M | -$130.2M | -$114.8M |
| EBITDA | -$101.4M | -$124.3M | -$117.8M | -$110.5M |
| Beneficio Neto | -$106.4M | -$130.6M | -$122.9M | -$91.2M |
| BPA | $-1.17 | $-1.37 | $-1.28 | $-0.94 |
| BPA Diluido | $-1.17 | $-1.37 | $-1.28 | $-0.94 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $315.5M | $239.8M | $456.6M | $943.8M | $1.17B | $923.0M | $211.9M | $389.5M | $298.3M | $355.2M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | $521.7M | $1.46B | $1.60B | $1.30B | $1.61B | $1.63B |
| Cuentas por Cobrar | $3.2M | $2.6M | $88000 | $99000 | $10.8M | $305000 | 0 | $200.0M | $25.0M | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $320.2M | $248.4M | $466.4M | $987.5M | $1.72B | $2.42B | $1.85B | $1.91B | $1.94B | $1.99B |
| Inmovilizado Material | $21.0M | $18.9M | $18.5M | $72.8M | $93.0M | $312.0M | $320.6M | $305.9M | $277.6M | $247.6M |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | $399000 | $344000 | $289000 | $235000 | $180000 | $125000 | $71000 | $16000 | 0 | 0 |
| Activos Totales | $345.0M | $271.3M | $489.0M | $1.07B | $1.83B | $2.75B | $2.24B | $2.23B | $2.24B | $2.27B |
| Cuentas por Pagar | $4.6M | $1.6M | $5.1M | $5.9M | $9.1M | $14.8M | $27.4M | $38.1M | $14.7M | $11.1M |
| Deuda a Corto | 0 | 0 | 0 | $8.5M | $11.4M | $12.2M | $15.8M | $15.6M | $17.3M | $18.6M |
| Pasivos Corrientes | $22.0M | $14.5M | $27.7M | $57.1M | $94.3M | $119.9M | $121.1M | $108.8M | $87.8M | $149.1M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $188.2M |
| Pasivos Totales | $112.1M | $83.5M | $96.8M | $127.3M | $163.7M | $352.4M | $367.6M | $346.8M | $310.0M | $343.4M |
| Reservas | -$57.1M | -$125.4M | -$291.6M | -$224.7M | -$573.6M | -$195.9M | -$846.1M | -$999.7M | -$1.37B | -$1.95B |
| Patrimonio Neto | $232.8M | $187.8M | $392.2M | $939.4M | $1.66B | $2.40B | $1.88B | $1.88B | $1.93B | $1.92B |
| Deuda Total | 0 | 0 | 0 | $52.5M | $61.4M | $225.0M | $244.0M | $238.6M | $223.7M | $394.9M |
| Deuda Neta | -$315.5M | -$239.8M | -$456.6M | -$891.2M | -$1.63B | -$2.15B | -$1.57B | -$1.46B | -$1.68B | -$1.58B |
| Capital Circulante | $298.2M | $233.9M | $438.6M | $930.4M | $1.62B | $2.30B | $1.73B | $1.80B | $1.85B | $1.84B |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $290.0M | $355.2M | $423.3M | $291.3M |
| Activos Totales | $2.25B | $2.27B | $2.73B | $2.65B |
| Pasivos Totales | $329.3M | $343.4M | $911.3M | $904.2M |
| Patrimonio Neto | $1.92B | $1.92B | $1.81B | $1.75B |
| Deuda Total | $403.8M | $394.9M | $787.6M | $783.7M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$23.2M | -$68.4M | -$165.0M | $66.9M | -$348.9M | $377.7M | -$650.2M | -$153.6M | -$366.3M | -$581.6M |
| Amortizaciones | $925000 | $3.0M | $3.5M | $4.7M | $9.2M | $18.0M | $24.2M | $19.8M | $19.3M | $19.5M |
| Compensación en Acciones | $10.8M | $18.9M | $35.0M | $44.1M | $66.0M | $102.4M | $97.9M | $81.0M | $86.6M | $72.5M |
| Cambio en Capital Circulante | $1.8M | -$25.4M | $10.6M | -$48.4M | $33.4M | $26.9M | $19.8M | -$193.6M | $156.3M | $71.9M |
| Flujo de Caja Operativo | -$55.3M | -$70.1M | -$96.2M | $56.7M | -$238.4M | $539.0M | -$495.7M | -$260.4M | -$142.8M | -$345.0M |
| Inversiones (CapEx) | -$3.0M | -$7.8M | -$2.8M | -$6.7M | -$18.4M | -$81.7M | -$37.2M | -$9.5M | -$1.9M | -$914000 |
| Adquisiciones | -$100000 | 0 | 0 | 0 | $522.8M | $953.7M | $221.5M | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | -$57000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$58.3M | -$77.9M | -$99.0M | $50.0M | -$256.7M | $457.3M | -$532.9M | -$269.8M | -$144.7M | -$345.9M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$84.6M | -$92.6M | -$108.9M | -$192.4M |
| Inversiones (CapEx) | -$74000 | -$517000 | -$504000 | -$1.2M |
| Flujo de Caja Libre | -$84.7M | -$93.1M | -$109.4M | -$193.5M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $16.6M | $18.1M | 0 | $33.6M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | +693.9% | -92.4% | +9169.8% | -99.8% | +126893.2% | -100.0% | +84762.4% | -90.5% | -90.0% |
| Crecimiento Beneficio Neto (anual) | | -194.6% | -141.4% | +140.5% | -621.8% | +208.3% | -272.2% | +76.4% | -138.4% | -58.8% |
| Crecimiento BPA (anual) | | +9.5% | -101.2% | +135.8% | -530.1% | +194.0% | -268.2% | +76.8% | -123.7% | -49.1% |
| Cambio en Acciones (anual) | | +226.8% | +19.7% | +18.7% | +15.8% | +21.9% | -3.3% | +1.9% | +6.5% | +6.6% |
| Crecimiento FCF (anual) | | -33.6% | -27.1% | +150.5% | -613.5% | +278.1% | -216.5% | +49.4% | +46.4% | -139.1% |
| Margen Bruto | -717.9% | -70.3% | -3541.9% | 38.1% | -37369.7% | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| Margen Operativo | -1319.3% | -157.7% | -5087.8% | 16.1% | -49295.5% | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% |
| Margen EBITDA | -264.7% | -150.3% | -4975.2% | 17.8% | -48018.2% | 43.5% | -143653.2% | -35.4% | -981.2% | -15911.3% |
| Margen Neto | -449.3% | -166.7% | -5281.1% | 23.1% | -48520.9% | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |
| Margen FCF | -1129.5% | -190.0% | -3169.4% | 17.3% | -35705.7% | 50.1% | -122231.4% | -72.9% | -413.4% | -9855.5% |
| Tasa Impositiva Efectiva | -2.1% | -2.6% | -0.3% | 0.7% | -0.2% | 0.5% | 0.0% | -1.9% | -1.0% | -0.6% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-4.76 | $-1.94 | $-2.06 | $0.88 | $-3.89 | $5.69 | $-6.85 | $-3.41 | $-1.71 | $-3.85 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $12.3M | $40.0M | $48.0M | $54.4M | $65.9M | $75.9M | $77.7M | $79.2M | $84.4M | $89.9M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Margen bruto | -1534.39% |
| Margen operativo | -3971.53% |
| Margen neto | -3368.72% |
Salud financiera
| Deuda / Patrimonio | 0.45 |
| Ratio corriente | 17.85 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -10.72 | -13.73 | -8.31 | 49.52 | -28.94 | 15.25 | -4.86 | -32.27 | -9.07 | -8.11 |
| P/VC | 1.07 | 5.00 | 3.49 | 3.53 | 6.07 | 2.40 | 1.69 | 2.63 | 1.72 | 2.45 |
| P/V | 48.09 | 22.89 | 438.61 | 11.44 | 14043.89 | 6.30 | 7248.62 | 13.40 | 94.87 | 1343.50 |
| Margen Bruto | -717.9% | -70.3% | -3541.9% | 38.1% | -37369.7% | 88.9% | -25186.7% | 64.8% | -215.0% | -6537.0% |
| Margen Operativo | -1319.3% | -157.7% | -5087.8% | 16.1% | -49295.5% | 40.9% | -154394.7% | -60.1% | -1333.0% | -16191.4% |
| Margen Neto | -449.3% | -166.7% | -5281.1% | 23.1% | -48520.9% | 41.4% | -149122.7% | -41.5% | -1046.4% | -16569.8% |